Compare Chewy Inc (CHWY) vs GSK plc (GSK) Price & Performance

Chewy IncTrade

GSK plcTrade

Price performance (Past 24H)

Key statistics

Chewy Inc vs GSK plc — how do they compare? Chewy Inc trades at $21.75 (market cap $8.33B), while GSK plc trades at $51.35 (market cap $101.55B). The key difference: GSK plc is far larger — about 12.2× Chewy Inc's market cap, and GSK plc pays a 3.5% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.

	CHWY	GSK
Market Cap	$8.33B	$101.55B
Sector	Consumer Cyclical	Health
52-Week High	$42.33	$61.18
52-Week Low	$17.51	$36.20
Enterprise Value	$8.30B	$122.16B
Dividend Yield	—	3.5%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chewy Inc

Chewy (CHWY) trades at $20.32, down 2.68% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported $11.86B revenue for 2025 with net income of $392.74M, showing improved profitability. Recent news highlights expansion in pet healthcare and AI-driven operational efficiency, though Q1 2026 earnings missed expectations.

The outlook is mixed: strong analyst consensus (81.58% buy ratings) and a $34.92 price target suggest upside, but near-term risks include consumer trade-down pressures and competitive threats. Long-term growth drivers in pet care and margin expansion offer potential, yet macroeconomic headwinds and execution risks warrant caution.

GSK plc

GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.

GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CHWY

Chewy posts strong Q1 sales growth and profitability, maintaining a Strong Buy rating despite macro challenges.Seeking Alpha · 1 day agoBullish Chewy upgraded to Buy after 40% stock drop and improving fundamentals in a growing pet market.Seeking Alpha · 1 day agoBullish Chewy remains a 'Buy' despite 40% YTD drop and lowered 2026 sales guidance amid macro challenges.Seeking Alpha · 4 days agoNeutral View details →

GSK

UBS keeps GSK neutral, eyes CEO's strategy update over Q2 results and pipeline plansProactive Investors - Finance · 2 days agoNeutral UBS keeps GSK neutral, eyes CEO's strategy update and pipeline reprioritization after Nuvalent dealProactive Investors · 2 days agoNeutral View details →

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.